Labour productivity losses caused by premature death associated with hepatitis C in Spain

European Journal of Gastroenterology and Hepatology

Volumn 27, Issue 6, 2015, Pages 631-637

  Oliva Moreno, Juan ^a   Peña Longobardo, Luz M ^a   Alonso, Sonia ^b   Fernández Bolaños, Antonio ^a   Gutiérrez, María Luisa ^b   Hidalgo Vega, Álvaro ^a   De La Fuente, Elsa ^b   Fernández Rodríguez, Conrado M ^b  

^a UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

Author keywords

hepatitis C; human capital approach; productivity losses; social costs

Indexed keywords

AGED; ARTICLE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MIXED INFECTION; PREMATURE MORTALITY; PRIORITY JOURNAL; PRODUCTIVITY; PRODUCTIVITY LOSSES; SENSITIVITY ANALYSIS; SIMULATION; SPAIN; CHRONIC HEPATITIS C; COMPLICATION; COMPUTER SIMULATION; COST OF ILLNESS; ECONOMICS; EMPLOYMENT; EPIDEMIOLOGY; LIVER TUMOR; MORTALITY; STATISTICS AND NUMERICAL DATA; THEORETICAL MODEL; VIROLOGY;

CARCINOMA, HEPATOCELLULAR; COINFECTION; COMPUTER SIMULATION; COST OF ILLNESS; EFFICIENCY; EMPLOYMENT; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MODELS, THEORETICAL; MORTALITY, PREMATURE; SPAIN;

EID: 84957709545     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000336     Document Type: Article

References (71)

1. Deuffic-Burban S, Deltenre P, Buti M, Stroffolini T, Parkes J, Mühlberger N, et al. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology 2012; 143:974-985.e14.
2. Global Burden Of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44:20-29.
3. De Bruijne J, Weegink CJ, Jansen PL, Reesink HW. New developments in the antiviral treatment of hepatitis C. Vox Sang 2009; 97:1-12.
4. Miebertski N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. HCV-related burden of disease in Europe: A systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009; 9:34.
5. Bruggmann P, Berg T, Ovrehus AL, Moreno C, Brandao Mello CE, Roudot-Thoraval F, et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat 2014; 21 (Suppl 1):5-33.
6. Bruix J, Barrera JM, Calvet X, Ercilla G, Costa J, Sanchez-Tapias JM, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989; 2:1004-1006.
7. Catalá Lopez F, Alvarez Martín E, Gènova Maleras R, Morant Ginestar C. Relationship between research funding in the Spanish National Health System and the burden of disease. Rev Esp Salud Publica 2009; 83:137-151.
8. Garcia-Ortuzarras A, Garcia-Ortu R, Garcia-Ortuzar V. Health investigation investment and the burden of disease because of hepatitis B and C. Rev Esp Salud Publica 2009; 83:587-588. author reply 589-591.
9. García-Fulgueiras A, García-Pina R, Morant C, García-Ortuzar V, Génova R, Alvarez E. Hepatitis C and hepatitis B-related mortality in Spain. Eur J Gastroenterol Hepatol 2009; 21:895-901.
10. Haj-Ali Saflo O, Hernández Guijo JM. Cost-effectiveness of chronic hepatitis C treatment in Spain. Gastroenterol Hepatol 2009; 32:472-482.
11. Buti M, Casado MA, Esteban R. Evaluating the cost of sustained virologic response in naive chronic hepatitis C patients treated á La carte. Aliment Pharmacol Ther 2007; 26:705-716.
12. Casado Gómez MA, Alvarez-Rubio L, Miró Manero S, Mariño Hernández EL, Buti Ferret M. Budget impact analysis of the treatment of chronic hepatitis C in a hospital. Farm Hosp 2006; 30:291-299.
13. Stahmeyer JT, Rossol S, Bert F, Antoni C, Demir M, Hinrichsen H, et al. Cost of treating hepatitis C in Germany: A retrospective multicenter analysis. Eur J Gastroenterol Hepatol 2014; 26:1278-1285.
14. Grossman M. The demand for health: A theoretical and empirical investigation. National Bureau of Economic Research. Occasional paper 119. New York: Columbia University Press; 1972.
15. Grossman M. The human capital model of the demand for health. In: Culyer Ayn JP, editor. Handbook of health economics. Amsterdam: North-Holland-Springer-Verlag; 2000.
16. Spanish National Statistics Institute. Annual Wage Structure Survey. 2012; Available at: Http://www.ine.es/dyngs/INEbase/en/operacion. htm?c =Estadistica-C&cid= 1254736061721&menu= ultiDatos&idp = 1254735976596. [Accessed 23 December 2014].
17. Spanish National Statistics Institute. Economically Active Population Survey. 2014. Availableat:http://www.ine.es/dyngs/INEbase/en/opera cion.htm?c=Estadistica-C&cid =1254736176918&menu = ultiDatos&idp=1254735976595. [Accessed 23 December 2014].
18. Spanish National Statistics Institute. Death statistic according to cause of death. 2012. Available at:http://www.ine.es/jaxi/menu.do?type= pcaxis&path=%2Ft15/p417&file= inebase&L =1 [Accessed 23 December 2014].
19. Garcrezea-Baziras A, Garcrezea-B R, Morant C, De Larrea-Baz NF, Alvarez E. Burden of disease related to hepatitis C and hepatitis B in Spain: A methodological challenge of an unfolding health problem. J Viral Hepat 2011; 18:e453-e460.
20. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45:529-538.
21. Hutchinson SJ, Bird SM, Goldberg DJ. Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland. Hepatology 2005; 42:711-723.
22. Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, et al. Hepatitis C virus related cirrhosis: Time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47:131-136.
23. Steenland K, Armstrong B. An overview of methods for calculating the burden of disease due to specific risk factors. Epidemiology 2006; 17:512-519.
24. Miettinen OS, Miettinen OS, Alexander HE, Leidy G, Hahn E. Proportion of disease caused or prevented by a given exposure, trait or intervention. Am J Epidemiol 1974; 99:325-332.
25. Levine B. What does the population attributable fraction mean? Prev Chronic Dis 2007; 4:A14.
26. Spanish National Statistics Institute. Consumer Price Index. 2014; Available at: Http://www.ine.es/jaxi/menu.do?type =pcaxis&path =% 2Ft25/p138&file =inebase&L =1. [Accessed 23 December 2014].
27. Akobundu E, Ju J, Blatt L, Mullins CD. Cost-of-illness studies: A review of current methods. Pharmacoeconomics 2006; 24:869-890.
28. Leal J, Luengo-Fernandez R, Gray A, Petersen S, Rayner M. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006; 27:1610-1619.
29. Oliva-Moreno J, L iva-Morenoe J, Montejo-Gonzezez AL, Osuna-Guerrero R, Duque-Gonzrero B. The socioeconomic costs of mental illness in Spain. Eur J Health Econ 2009; 10:361-369.
30. Naci H, Fleurence R, Birt J, Duhig A. Economic burden of multiple sclerosis: A systematic review of the literature. Pharmacoeconomics 2010; 28:363-379.
31. Luengo-Fernandez R, Leal J, Gray AM. Cost of dementia in the preenlargement countries of the European Union. J Alzheimers Dis 2011; 27:187-196.
32. Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: A population-based cost analysis. Lancet Oncol 2013; 14:1165-1174.
33. Dhaliwal HS, Nampoothiri RV. Daclatasvir plus sofosbuvir for HCV infection. N Engl J Med 2014; 370:1560.
34. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370:1889-1898.
35. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370:1973-1982.
36. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370:1879-1888.
37. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370:1993-2001.
38. Sulkowski MS, Jacobson IM, Nelson DR. Daclatasvir plus sofosbuvir for HCV infection. N Engl J Med 2014; 370:1560-1561.
39. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlidne M, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1604-1614.
40. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368:1878-1887.
41. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368:1867-1877.
42. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1594-1603.
43. Zeuzem S, Soriano V, Asselah T, Bronowicki JP, Lohse AW, Müllhaupt B, et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013; 369:630-639.
44. Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): An open-label, randomised, phase 2 trial. Lancet 2014; 383:515-523.
45. Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: The best interferon-free combinations. Liver Int 2014; Suppl 1 (Suppl 1):69-78.
46. Pawlotsky JM. New hepatitis C therapies: The toolbox, strategies, and challenges. Gastroenterology 2014; 146:1176-1192.
47. Hu J, Meek P. Health-related quality of life in individuals with chronic obstructive pulmonary disease. Heart Lung 2005; 34:415-422.
48. Sachs J. Macroeconomics and health: Investing in health for economic development Report of the Commission on Macroeconomics and Health Geneva. Switzerland: World Health Organization; 2001.
49. Shurcke M, Mckee M, Sauto-Arce R, Tsolova S, Mortensen J. The contribution of health to the economy in the European Union European Communities. Luxembourg: Office for Official Publications of the European Communities; 2005.
50. Knapp M. Hidden costs of mental illness. Br J Psychiatry 2003; 183:477-478.
51. Leigh JP, Bowlus CL, Leistikow BN, Schenker M. Costs of hepatitis C. Arch Intern Med 2001; 161:2231-2237.
52. Vietri J, Prajapati G, El Khoury AC. The burden of hepatitis C in Europe from the patients' perspective: A survey in 5 countries. BMC Gastroenterol 2013; 13:16.
53. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90:1562-1569.
54. Patruni B, Nolte E. Hepatitis C A projection of the healthcare and economic burden in the UK. Cambridge, UK: RAND Corporation; 2013. p. 58.
55. Shiell A, Law MG. The cost of hepatitis C and the cost-effectiveness of its prevention. Health Policy 2001; 58:121-131.
56. Su J, Brook RA, Kleinman NL, Corey-Lisle P. The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. Hepatology 2010; 52:436-442.
57. Manne V, Sassi K, Allen R, Saab S. Hepatitis C and work impairment: A review of current literature. J Clin Gastroenterol 2014; 48:595-599.
58. daCosta DiBonaventura M, Yuan Y, Wagner JS, L'Italien GJ, Lescrauwaet B, Langley P. The burden of viral hepatitis C in Europe: A propensity analysis of patient outcomes. Eur J Gastroenterol Hepatol 2012; 24:869-877.
59. Dibonaventura MD, Yuan Y, Lescrauwaet B, L'italien G, Liu GG, Kamae I, Mauskopf JA. Multicountry burden of chronic hepatitis C viral infection among those aware of their diagnosis: A patient survey. PLoS One 2014; 9:e86070.
60. Mahajan R, Xing J, Liu SJ, Ly KN, Moorman AC, Rupp L, et al. Mortality among persons in care with hepatitis C virus infection: The Chronic Hepatitis Cohort Study (CHeCS), 2006-2010. Clin Infect Dis 2014; 58:1055-1061.
61. Rodriguez AE. Risk factors and associations for hepatitis C infection among Hispanic/Latino intravenous drug users in Miami-Dade County, Florida [dissertation]. Miami: Florida International University; 2012. Available at: Http://digitalcommons.fiu.edu/cgi/viewcontent.cgi?article= 1857&context=etd. [Accessed 23 February 2015].
62. Domlerasz A, Bruguera M, Vidal J, Plans P, Salleras L. Communitybased seroepidemiological survey of HCV infection in Catalonia, Spain. J Med Virol 2001; 65:688-693.
63. Sacristll B, Gastastlla MI, Elena A, Sacristll M, Barcenilla J, Garcen JC, Yangenil J. Seroepidemiologic study of hepatitis C virus infection in a general population from the region of La Rioja, Spain. Med Clin (Barc) 1996; 107:331-335.
64. Mohammad A, Carey JJ, Storan E, Scarry M, Coughlan RJ, Lee JM. Prevalence of fibromyalgia among patients with chronic hepatitis C infection: Relationship to viral characteristics and quality of life. J Clin Gastroenterol 2012; 46:407-412.
65. Koopmanschap MA, Rutten FF, Van Ineveld BM, Van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14:171-189.
66. Johannesson M, Karlsson G. The friction cost method: A comment. J Health Econ 1997; 16:249-255. discussion 257-259.
67. Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998; 13 (Pt 1):1-7.
68. Oliva-Moreno J. Loss of labour productivity caused by disease and health problems: What is the magnitude of its effect on Spain's economy? Eur J Health Econ 2012; 13:605-614.
69. Krol M, Brouwer W, Rutten F. Productivity costs in economic evaluations: Past, present, future. Pharmacoeconomics 2013; 31:537-549.
70. Zhang W, Bansback N, Anis AH. Measuring and valuing productivity loss due to poor health: A critical review. Soc Sci Med 2011; 72:185-192.
71. Nyman J. Productivity costs revisited: Toward a new US policy. Health Econ 2012; 21:1387-1401.